Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00685425 · ClinicalTrials.gov registry record · Phase 3
Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 62
- Enrollment target
NCT00685425 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 62 participants.
The verdict
NCT00685425, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 62 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate, using an exercise challenge approach, the dose response of levalbuterol HFA MDI in adolescent and adult subjects with asthma
Interventions
- DRUG Levalbuterol HFA MDI
- DRUG Racemic Albuterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2002-10 |
| Est. Completion | 2003-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00685425
The ClinicalTrials.gov registry entry for NCT00685425 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Levalbuterol HFA MDI is the first listed.
NCT00685425 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00685425 about?
NCT00685425 is a clinical study titled "Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol". The purpose of this study is to investigate, using an exercise challenge approach, the dose response of levalbuterol HFA MDI in adolescent and adult subjects with asthma
What is the current status of trial NCT00685425?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 62 participants. The study started on 2002-10. Estimated completion is 2003-03.
What interventions are being tested in trial NCT00685425?
The interventions under investigation include: Levalbuterol HFA MDI (DRUG), Racemic Albuterol (DRUG).
Who is sponsoring clinical trial NCT00685425?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.